Catalyzing innovative R&D for neglected tropical diseases, malaria, and tuberculosis
WIPO Re:Search is led by the World Intellectual Property Organization (WIPO) in partnership with BVGH and several leading pharmaceutical companies. Consortium membership includes academic and nonprofit research institutions, governmental and non-governmental organizations, and budding biotechnology companies committed to addressing the unmet medical needs of the developing world. Our 80+ Members represent 23 countries from six continents, including 17 African institutions. Download our Member list here.
The aim of the consortium is to accelerate the development of new drugs, vaccines, and diagnostics for neglected tropical diseases, malaria, and tuberculosis. BVGH creates partnerships that connect private industry’s assets and resources to qualified academic and nonprofit researchers with novel product discovery or development ideas.
BVGH’s leadership is critical to the Consortium’s success. As the Partnership Hub Administrator, BVGH proactively examines scientists’ current neglected disease research and proposes novel collaboration opportunities with other Members. BVGH also fields requests from researchers, identifies Member organizations able to fulfill these requests, and helps forge mutually beneficial collaborations with clearly-defined roles, responsibilities, and expectations.
Read the most recent news in the WIPO Re:Search Snapshot.
Merck (MSD) and the University of California, San Francisco
A WIPO Re:Search agreement between the University of California, San Francisco (UCSF) and Merck allows the Center for Discovery and Innovation in Parasitic Diseases (CDIPD) at UCSF to obtain a set of Merck’s HMG Co-A reductase inhibitors (statins) and test these inhibitors against schistosomes. CDIPD is an interdisciplinary program that seeks to identify disease biomarkers, and to discover and develop new drugs and new vaccines for diseases of poverty. Conor Caffrey, the Schistosomiasis and Hookworm Core Director at CDIPD, will be leading the effort to screen Merck’s compounds against the parasite. Conor will utilize a novel whole-organism screening platform, designed to accelerate the identification of anti-schistosomal compounds, to assess the inhibitors’ activities against a specific schistosome target. “This is exactly the kind of opportunity our screening system is designed for. We are delighted to have Merck’s collaboration as an outstanding example of the pharmaceutical industry partners the CDIPD has worked with in the search for drugs to treat tropical infectious diseases. In this case, leveraging Merck’s knowledge and expertise in the statin field will accelerate our schistosomiasis research.” – Conor Caffrey
If you are interested in becoming a member of the consortium or learning more, please email Katy Graef at email@example.com.